Soleno Therapeutics (SLNO) Stock Surged Over 30% After Neurocrine’s $2.5 Billion Buyout Report

TLDR

• Following reports of a potential acquisition, Soleno Therapeutics (SLNO) saw its stock rise by more than 30% during premarket trading on Monday.
• Neurocrine Biosciences (NBIX) is reportedly in late-stage discussions to purchase Soleno for a sum exceeding $2.5 billion.
• Under the terms of the potential agreement, SLNO shares might be valued between the low and mid $50 range.
• According to the Financial Times, an official announcement could arrive as early as Monday, April 6.
• In premarket action, Neurocrine shares dropped by 0.4% following the announcement.

(SeaPRwire) –   2026 had been a challenging year for Soleno Therapeutics, with shares down approximately 14% year-to-date, but the situation shifted rapidly on Monday morning.

Soleno Therapeutics, Inc., SLNO

According to a report by the Financial Times, Neurocrine Biosciences is engaged in advanced negotiations to acquire the rare disease-focused biotech company for over $2.5 billion. This news drove SLNO up by more than 30% in premarket trade.

Neurocrine nears $2.5bn-plus deal for biotech behind obesity disorder treatment https://t.co/t7RIhvgwIb

— Financial Times (@FT) April 6, 2026

The transaction is expected to place Soleno’s valuation in the low-to-mid $50s per share range. With negotiations proceeding swiftly, the FT indicated that an agreement could be reached by Monday.

Soleno’s primary asset is Vykat XR, a medication released last year designed to address hyperphagia, a condition associated with Prader-Willi syndrome. Characterized by intense and unrelenting hunger, hyperphagia can result in severe health issues such as obesity, cardiovascular disease, choking, and stomach rupture.

Occurring in approximately one out of every 15,000 live births, Prader-Willi syndrome is a rare genetic disorder. Vykat XR stands as the first commercially available drug authorized to treat the hunger symptoms related to this condition.

Projections by analysts suggest Vykat XR could achieve peak yearly sales of $2.3 billion, a figure that undoubtedly attracted Neurocrine’s interest.

Neurocrine Moves Into Rare Disease

Neurocrine currently boasts a market capitalization of approximately $13.21 billion. Its product lineup features Ingrezza, used for treating involuntary movements associated with’s disease, as well as various other approved therapies and a robust pipeline of candidates.

The addition of Vykat XR would establish a presence for Neurocrine in the orphan drug and rare disease sector, markets typically characterized by strong pricing power and minimal competition.

On Monday, Neurocrine shares experienced a slight decline of 0.4% in premarket trading. This is a common market response when a company announces an acquisition, as investors factor in the premium paid for the target.

SLNO’s Run-Up in Context

Despite the surge on Monday, SLNO was still down by about 14% for the year 2026 prior to this week. The equity had faced difficulties, even amidst analyst optimism regarding the commercial viability of Vykat XR.

Data from TipRanks shows a Strong Buy consensus rating for SLNO among 11 analysts. The average target price is $101.09, with the top estimate reaching $125.

While the reported acquisition price in the low-to-mid $50s range falls significantly short of these analyst targets, it still offers a substantial premium over SLNO’s recent trading levels.

Citing individuals with knowledge of the negotiations, the Financial Times report noted that talks are advancing positively and are quickly heading toward a potential deal.